Literature DB >> 56452

Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein.

P M Freedman, J R Autry, S Tokuda, R C Williams.   

Abstract

Prior sc immunization of BALB/c mice with 1 mg isolated M component of MOPC-11 mouse myeloma resulted in significant relative immunity to subsequent sc or ip challenge with 10(4) living cells from the same plasmacytoma. However, challenges of 10(5) and 10(6) tumor cells overcame immune status engendered by preimmunization with M component. Despite evidence for the specificity of the immunity induced by one isolated M component as opposed to another, no clear cytotoxic antibody, cell-mediated tumor-cell lysis, or predominance of either humoral or cell-mediated immune mechanisms were demonstrated. These findings were compatible with a relatively slight tumor-specific antigenicity of M components expressed on tumor surfaces, compared with the tumor specificity of other tumor-related, cell-surface antigens.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 56452     DOI: 10.1093/jnci/56.4.735

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  8 in total

Review 1.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

Review 2.  Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Authors:  Hyun Jun Park; Sattva S Neelapu
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

3.  An experimental immunocytoma model in /LOU/M/Ws1 X CFY/F1 rats: neoplastic cells as targets of the host's immune apparatus.

Authors:  E Puskás; F Uher; J Gergely; H Bazin
Journal:  Immunology       Date:  1984-07       Impact factor: 7.397

Review 4.  Vaccination strategies in follicular lymphoma.

Authors:  Shibichakravarthy Kannan; Sattva S Neelapu
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

5.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

Authors:  L W Kwak; H A Young; R W Pennington; S D Weeks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 6.  Therapeutic vaccine for lymphoma.

Authors:  Seung-Tae Lee; Sattva S Neelapu; Larry W Kwak
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

Review 7.  Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens.

Authors:  K Thielemans; J B Rothbard; S Levy; R Levy
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

8.  Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.

Authors:  Sheeba K Thomas; Soung-Chul Cha; D Lynne Smith; Kun Hwa Kim; Sapna R Parshottam; Sheetal Rao; Michael Popescu; Vincent Y Lee; Sattva S Neelapu; Larry W Kwak
Journal:  BMC Cancer       Date:  2018-02-13       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.